EyeBio

Back to Home

David Guyer, M.D.

David co-founded EyeBio with Anthony P. Adamis, M.D., in August 2021. Today he holds the title of EyeBio Co-founder, President, and Chief Executive Officer (CEO). David is also a Venture Partner at SV Health Investors and is Co-Founder and former CEO and Executive Chairman of Iveric Bio (previously Ophthotech). David served as Chairman of Iveric Bio’s board of directors from 2007 to 2017, as CEO from 2013 to 2017, and as Executive Chairman from 2017 to 2021. Under his leadership, Iveric Bio entered into a partnership with Novartis that, at the time, was one of the largest ex-U.S. partnering transactions in biotechnology industry history.

David has expansive medical, drug development, and commercial experience in ophthalmology. His expertise is highly sought after, and he has served on the boards of approximately 20 companies, both public and private. In addition to co-founding EyeBio and Iveric Bio, David co-founded Eyetech Pharmaceuticals Inc. and served as its CEO and member of the board of directors from 2000 until the company’s acquisition by OSI Pharmaceuticals, Inc. in November 2005.

Prior to co-founding Eyetech Pharmaceuticals, David was a professor and Chairman of the Department of Ophthalmology at New York University School of Medicine. David received a B.S. from Yale College and an M.D. from Johns Hopkins Medical School. He completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

Kate Bingham, DBE

As Managing Partner of SV Health Investors, Kate co-leads SV’s Biotech franchise, which has a long history of building high-value, successful new companies developing transformational medicines and bringing drugs from discovery to market. Kate’s investments, many of which are examples of SV’s company-creation approach to biotech investing, include a wide range of drug discovery and development companies focused on different clinical areas. Her investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.  

From May to December 2020 Kate served as Chair of the UK Vaccine Taskforce (VTF), which was set up in response to the COVID-19 pandemic to lead the UK’s efforts to discover and manufacture a COVID-19 vaccine. She was awarded a Dame Commander (DBE) rank in the Queen’s Birthday Honours in June 2021 for services relating to the procurement, manufacture, and distribution of COVID-19 vaccines.

Kate serves on the Board of the Francis Crick Institute and won the BioIndustry Association UK Lifetime Achievement Award in January 2017. Prior to joining SV, Kate worked in business development for Vertex Pharmaceuticals and at Monitor Company, a strategy consulting firm. Kate has a first-class degree in Biochemistry from Oxford University and an M.B.A. from Harvard Business School, where she was a Baker Scholar.

Anthony P. Adamis, M.D.

Tony co-founded EyeBio with David Guyer, M.D., in August 2021. Today he holds the title of Chief Scientific Officer after previously serving as the company’s Director and Chair of the Advisory Board. He is best known for his co-discovery of the central role of vascular endothelial growth factor (VEGF) in two leading causes of blindness: neovascular age-related macular degeneration (nAMD) and diabetic retinopathy. Conducted at Harvard in the 1990s, this research led to Tony’s shared receipt of the Antonio Champalimaud Award, the highest honor in vision science, and to his election to the National Academy of Medicine.

At Eyetech, where he was a Co-Founder, and later at Genentech (now a wholly owned member of The Roche Group), Tony helped lead the development of the first anti-VEGF drugs for the treatment of nAMD, diabetic macular edema (DME), diabetic retinopathy, retinal vein occlusion, and myopic choroidal neovascularization. With the introduction of anti-VEGF drugs, legal blindness from nAMD and DME has been reduced by half around the world.

At Genentech, Tony helped lead the development of the first long-acting delivery technology for a biologic drug (port delivery system) and the first bispecific antibody for nAMD and DME (faricimab). Over the course of his career, Tony has helped develop 20 medicines across 30 indications, resulting in seven U.S. Food and Drug Administration (FDA) Breakthrough Designations and 25 FDA approvals. Tony received his M.D. from the University of Chicago, his ophthalmology training at the University of Michigan, and his fellowship training at Harvard University. He completed his research training in vascular biology with Judah Folkman, M.D., at Boston Children’s Hospital.

Srinivas Akkaraju, M.D., Ph.D.

Srinivas is the Founder and Managing General Partner at Samsara BioCapital. His previous positions include General Partner of Sofinnova Ventures, Managing Director of New Leaf Venture Partners, and Co-Founder and Managing Director at Panorama Capital, LLC, a private equity firm. Prior to co-founding Panorama Capital, Srinivas was a Partner with J.P. Morgan Partners. He also worked in Business and Corporate Development at Genentech (now a wholly owned member of The Roche Group), a biotechnology company.

Prior to joining Genentech, Srinivas was a graduate student at Stanford University, where he received his M.D. and a Ph.D. in Immunology. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University. Srinivas serves as a Director of Chinook Therapeutics, Intercept Pharmaceuticals, Syros Pharmaceuticals, and Jiya Acquisition Corp. Previously, he served as a Director on the boards of Seattle Genetics, Principia Biopharma, Aravive, Inc., Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp., and Amarin Corporation.

Bernard Davitian

Bernard joined Omega Funds in 2020. He has extensive experience in the life sciences and biotech industry, marked by a number of successful transactions involving financings and M&A. Bernard currently serves on the Board of Directors of EyeBio, Endeavor BioMedicines, Lexeo Therapeutics, Upstream Bio and Vanqua Bio.

Bernard previously served as SVP and Managing Director at Sanofi Ventures, having first joined Sanofi in 2010 as Vice President, Deputy Global Head, Business Development. Over his 7-year tenure, Sanofi Ventures invested in 28 new companies and generated 14 exits (12 NASDAQ IPOs, 1 trade sale and 1 option deal).

Prior to Sanofi, Bernard held CEO, CFO and other leadership roles at Fovea Pharmaceuticals (which was sold to Sanofi in 2009 in a $540 million cash transaction), Neurotech Pharmaceuticals, Transgene (which successfully raised $100 million in a 1998 IPO on the NASDAQ/EuroNext) and Institut Mérieux (now Sanofi Pasteur).

Bernard received his Executive MBA from The Wharton School of the University of Pennsylvania and his MSc in Management from Emlyon Business School.

Evelyn Harrison

Evelyn is the Senior Vice President & Chief Clinical Operations Officer at IVERIC bio, Inc. and a member of their Executive Leadership Team. Prior to joining IVERIC bio (formerly Ophthotech Corporation) in 2007, Evelyn was with Eyetech Pharmaceuticals, Inc. where she held the positions of Vice President and Senior Vice President of Clinical Research and Development. While at Eyetech, Evelyn played a key role in the development and approval of Macugen® (pegaptanib sodium) for the treatment of wet age-related macular degeneration.

Evelyn has more than 30 years of management, clinical research and development experience in the biotech industry. Her career started at Hoffmann-LaRoche where she held several positions in clinical development and was responsible for the development and implementation of strategic programs for Roche’s oncology franchise. She has worked on all phases of global clinical trials in multiple therapeutic areas such as ophthalmology, bone marrow transplantation, organ transplantation, and virology.

Evelyn holds a BA degree in Biology from Hofstra University and an MBA from Manhattan College.